Arrowhead Pharmaceuticals, Inc. Earnings

Arrowhead Pharmaceuticals, Inc.’s revenue jumped 987.25% since last year same period to $256.47Mn in the Q3 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated 823.66% jump in its revenue since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s net profit jumped 86.07% since last year same period to $-23.75Mn in the Q3 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated 86.45% jump in its net profits since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s net profit margin jumped 98.72% since last year same period to -9.26% in the Q3 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated 98.53% jump in its net profit margins since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 75.65% jump from last quarter’s estimates.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.21.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Arrowhead Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.